✦ LIBER ✦

Aclacinomycin A in the treatment of multiple myeloma: A Southwest Oncology Group study

✍ Scribed by Chatchada Karanes; John Crowley; Laxmidas Sawkar; Bill L. Tranum; William J. Hicks; John D. Bonnet; Lyubica Dabich; Bruce W. Dana; Sydney Salmon

Publisher: Springer US
Year: 1990
Tongue: English
Weight: 294 KB
Volume: 8
Category: Article
ISSN: 0167-6997
DOI: 10.1007/bf00216933

No coin nor oath required. For personal study only.

✦ Synopsis

Fifty-two patients with progressive resistant multiple myeloma were entered in this Southwest Oncology Group Phase II study, using weekly intravenous Aclacinomycin A. Of forty-three evaluable patients for response, there was one partial remission of 2 years duration and two sustained clinical improvements with 25% reduction in paraprotein. Major toxicity seen was severe myelosuppression and significant nausea and vomiting requiring dose reduction and delay of the scheduled treatment. Cardiac arrhythmia was seen in one patient. Chronic daily schedule or continuous IV infusion is recommended for future study.

📜 SIMILAR VOLUMES

Adriamycin in the treatment of childhood

Adriamycin in the treatment of childhood acute leukemia a southwest oncology group study

✍ Abdelsalam H. Ragab; Wataru W. Sutow; Diane M. Komp; Kenneth A. Starling; George 📂 Article 📅 1975 🏛 John Wiley and Sons 🌐 English ⚖ 316 KB 👁 2 views

Adriamycin in the treatment of childhood

Adriamycin in the treatment of childhood solid tumors. A southwest oncology group study

✍ Abdelsalam H. Ragab; Wataru W. Sutow; Diane M. Komp; Kenneth A. Starling; George 📂 Article 📅 1975 🏛 John Wiley and Sons 🌐 English ⚖ 327 KB 👁 2 views

CCNU and bleomycin in the treatment of c

CCNU and bleomycin in the treatment of cancer: A southwest oncology group study

✍ Hoogstraten, Barth ;Haas, Charles D. ;Haut, Arthur ;Talley, Robert W. ;Rivkin, S 📂 Article 📅 1975 🏛 John Wiley and Sons 🌐 English ⚖ 570 KB

## Abstract CCNU and Bleomycin, alone or in combination, were used to treat 397 evaluable cases of advanced cancer. Responses defined as 50% or greater reduction in all tumor masses occurred in 13/35 lymphomas, 8/50 brain cancers, and 28/312 other solid tumors. Hematologic toxicity of a life‐threat

Adriamycin in combination for the treatm

Adriamycin in combination for the treatment of breast cancer. A southwest oncology group study

✍ Dr. B. Tranum; B. Hoogstraten; A. Kennedy; C. B. Vaughn; B. Samal; T. Thigpen; S 📂 Article 📅 1978 🏛 John Wiley and Sons 🌐 English ⚖ 431 KB 👁 2 views

Patients with advanced breast cancer who had not previously received chemotherapy were treated on a three-arm prospective study: adriamycin day 1 plus 5-FU on day 1 and 8 (AF), adriamycin day 1 , plus 5-FU day 1 and 8 , and cyclophosphamide day 1 (AFC), and adriamycin day 1 plus 5-FU day 1 and 8 , c

Adjuvant chemotherapy in primary treatme

Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. A southwest oncology group study

✍ Wataru W. Sutow; Margaret P. Sullivan; Donald J. Fernbach; Ayten Cangir; Stephen 📂 Article 📅 1975 🏛 John Wiley and Sons 🌐 English ⚖ 346 KB 👁 2 views

Bisantrene hydrochloride in gastric aden

Bisantrene hydrochloride in gastric adenocarcinoma: A southwest oncology group study

✍ Panettiere, Frank J. ;Jones, Stephen E. ;Oishi, Noboru ;Eyre, Harmon J. ;O'Bryan 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 257 KB

Because "the standard" chemotherapy for advanced gastric adenocarcinoma, the FAM combination of 5-fluorouracil, adriamycin, and mitomycin, is only minimally effective, there is a clear need for other choices. Therefore, the Southwest Oncology Group tested the new adriamycin analog, bisantrene, hopin